Ubie and Nucleus Genomics Partner to Improve Access to Genetic Screening

What You Should Know: 

– Ubie, a global healthcare AI platform, and Nucleus Genomics, a next-generation genetic testing and analysis company, today announced the successful outcomes of their partnership aimed at improving access to genetic screening and early disease detection. 

– The collaboration leverages Ubie’s AI-powered Symptom Checker and Nucleus Genomics’ sophisticated genetic testing capabilities to identify individuals who may have undiagnosed genetic conditions and connect them with appropriate screening options.

Advanced Genetic Testing to Identify Undiagnosed Conditions 

Genetic disorders can cause a wide range of health issues, and early detection through genetic testing is crucial for informed medical decision-making, personalized treatment plans, and proactive health management.

Key focus areas of the partnership include:

• Early detection of genetic predispositions: Identifying individuals at risk for various health conditions based on their genetic makeup.
• Improved access to genetic screening: Expanding access to genetic testing for underserved populations.
• Enhanced patient education: Providing personalized information about genetic factors in common and rare diseases.
• Personalized health insights: Combining symptom analysis with genetic markers to deliver tailored health recommendations.

Ubie’s platform helped Nucleus Genomics reach over 277,000 patients in just four months.  The collaboration expanded Nucleus Genomics’ reach to a broader demographic, including individuals across various age groups and with a focus on female users.

The Power of Whole-Genome Sequencing

Nucleus Genomics offers comprehensive genetic testing through whole-genome sequencing, analyzing 100% of a patient’s DNA. This provides a more complete picture of genetic risk factors for over 900 conditions compared to traditional microarray testing, which analyzes less than 0.1% of the genome.

“This partnership represents a significant step forward in democratizing access to genetic testing. This will empower patients, who are already actively searching for answers, to take control of their care,” said Kota Kubo, Co-Founder and CEO of Ubie. “This partnership is an example of how connecting disparate pieces of healthcare and providing patients with the insights they need can have an impact on appropriate care and outcomes.”